Cancer immunotherapy has revolutionized oncology by harnessing the immune system to combat malignant tumors, driving significant advancements in cancer treatment. However, due to the complex interplay between tumor cells and immune cells, many patients fail to achieve durable responses. Mast cells are bone marrow-derived immune cells and a crucial component of the innate immune system. Previously, mast cells were primarily recognized for their roles in allergic and inflammatory responses. In recent years, increasing attention has been directed toward their dual functions in the tumor microenvironment during cancer progression, highlighting the potential of mast cell-targeted strategies in cancer immunotherapy. This review summarized recent advances about the dual role of mast cells in the tumor microenvironment. At the same time, this review further evaluates the translational potential of mast cells as predictive markers and innovative therapeutic targets for cancer immunotherapy. By elucidating these mechanisms, this review aims to bridge the gap between preclinical insights and clinical applications, offering a roadmap for mast cell-centric approaches to overcome resistance and improve outcomes in cancer immunotherapy.
Li et al. (Sat,) studied this question.